Advancing COPD Drug Development Through Biomarker-Driven, Clinically Meaningful Innovation
After years of limited progress, COPD drug development is entering a pivotal moment. Recent milestones, including Sanofi's approval of the first biologic therapy, renewed Big Pharma engagement, and multi‑billion‑dollar deals, have reignited scientific, commercial, and investor interest in a disease area long viewed as high risk and high attrition. At the same time, advances in disease biology, translational science, and clinical development tools are creating new opportunities to succeed where previous approaches failed.
The COPD Drug Development Summit brings the industry together at this inflection point. This inaugural, industry‑led meeting convenes leaders from discovery through late‑stage development to explore how emerging modalities, smarter trial design, and more precise endpoints can unlock the next generation of COPD therapies. Built for biotech and pharmaceutical decision‑makers, the event focuses on practical strategies to reduce development risk, accelerate clinical proof‑of‑concept, and deliver meaningful benefit to heterogeneous COPD patient populations.
Join 65+ senior experts from leading and emerging organizations, including Johnson & Johnson, Sanofi, AstraZeneca, Merck, Ethris, Generate Biomedicines, and Connect Biopharma, for a highly focused forum combining scientific insight, case studies, and networking.
With momentum returning to the space, this is a critical opportunity to align on what it will take to translate renewed investment into approved, disease‑modifying treatments for COPD.
I truly appreciate the scale of the summit and the diversity of attendees, ranging from small biotech and large pharma to clinicians and academics. This diversity creates a valuable opportunity for cross-disciplinary learning.
Research Scientist, Inflammation & Drug Discovery, Takeda
I thought the quality of the actual content and ability to engage the audience frequently was stellar.
Medical Director, Vertex Pharmaceuticals
The overall agenda of topics and discussions were great, but in particular I was glad to participate in the preconference workshops. I felt they were valuable for both those new to the filed or experienced.
Principal Scientist, Research, Abbvie
Explore the Full Event Guide
- Network with 65+ discovery, translational, clinical and regulatory experts from the likes of Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Connect Biopharma, Generate Biomedicines, Ethris, and many more
- Critical debates on regulatory expectations and opportunities to validate novel endpoints that de‑risk development and support faster, more confident approvals
- Expert perspectives on combining imaging, molecular, and clinical data to build a more holistic view of COPD biology and improve translational success
- Hear from 16+ respiratory specialists and C-level executives presenting novel targets and clinical trial strategies
- 3 days of essential industry collaboration including over 6 hours of specialized networking
Attending Companies Include
Explore the Brand-New Agenda
Gain direct insight into how leading pharma and biotech teams are advancing COPD pipelines, with case studies and discussions focused on biomarker-led trials, emerging biologics, and strategies to overcome translational and regulatory barriers.
Partner With Us
Position your organisation alongside leading solution providers and engage directly with pharma and biotech teams actively advancing COPD pipelines, looking for partners to accelerate development.
Join a Highly Curated Respiratory Community
Build meaningful connections with the people shaping next-generation COPD